OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Cancer is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Editorial Board	476
Standardization of viability assays and high-content live-cell imaging protocols for large-scale drug testing in prostate cancer PDX-derived organoids	356
Corrigendum to ‘Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review [European Jour	235
Overcoming chemoresistance in triple negative breast cancer by bromodomain inhibition	206
Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”	193
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition	192
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma	171
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study	144
363 (PB351): Ferrous Iron Reactive (FIRE) delivery of diagnostic or therapeutic agents	143
306 (PB294): OMX-0407 a spectrum selective kinase inhibitor shows preclinical and clinical efficacy in Angiosarcoma, an indication of high unmet medical need	142
71 (PB059): The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-inhuman phase 1/2 study	134
A-222 Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment	122
A-262 Targeting the hyperactive STAT3/5 Pathway in Cutaneous T-Cell Lymphoma: superior efficacy of multi-kinase inhibitor IQDMA over conventional PUVA therapy	121
A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas	112
A-246 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation - report of 3 cases	111
A-288 Retrospective Clinicopathological Comparative Study between Hypopigmented Mycosis Fungoides and Pityriasis Lichenoides Chronica	106
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patien	97
10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis	94
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab	94
Gene expression-based prediction of pazopanib efficacy in sarcoma	93
Patient-led follow-up after curative colorectal cancer surgery: The primary outcome analysis of the prospective, multicentre FUTURE-primary implementation study	91
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer	87
84 (PB072): Discovery and characterization of potent inhibitors of the RNA editing enzyme ADAR1	85
387 (PB375): Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins	83
405 (PB393): A combination of AURK inhibitor and HDAC inhibitor can restrain Anaplastic Thyroid Cancer aggressiveness: a drug repurposing story	78

250 (PB238): In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia	77
272 (PB260): Establishment and evaluation of radioresistant models from patient derived tissue	76
277 (PB265): Comparative analysis of immune responses in a 3D ex vivo patient tissue platform across diverse cancer types	76
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC	76
417 (PB405): Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells	75
300 (PB288): Combination of RAS(ON) Multi-Selective and G12D-Selective Inhibitors Improves Antitumor Activity and Enhances Antitumor Immunity in Preclinical Models of KRASG12D-Driven Cancers	75
441 (PB429): GRC 70267, a novel first-generation small molecule degrader of IRAK-M with anti-tumor activity	70
210 (PB198): KRASmulti inhibition and checkpoint targeting therapy show strong combination potential in KRAS wild-type and KRASG12V-driven syngeneic mouse models of pancreatic cancer	70
334 (PB322): PARP1 inhibitor resistant cell line generation and DDR cell panel development	68
Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience	67
310 (PB298): Synergistic Anti-Tumor Effects of the Novel HDAC Inhibitor, ABT-301, with Immune Checkpoint Inhibitors in Colorectal Cancer Through Regulation of Immune Response and Anti-Angiogenesis	67
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients	67
Macular type of primary cutaneous B-cell lymphoma: extension of the clinical and histopathological patterns	65
Impact of Oncotype DX Recurrence Score and Nottingham Prognostic Index on adjuvant treatment in patients with axillary lymph node micrometastasis in early breast cancer	65
Spectrum of dermo-epidermic cutaneous gamma-delta lymphomas from a single center: clinical and phenotypic analysis of an heterogenous lymphoproliferative disorder	64
The role of a patient with breast cancer in a multidisciplinary team – from making a decision to changing the treatment option	63
Real world evidence from a Breast Screening pilot for the underprivileged: Experiences from Bruhat Bengaluru Mahanagara Palike hospitals	63
Metabolic profile associated with chemoresistance in ovarian cancer cells using metabolomics	60
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy	59
Discovery of Essential microRNA in Prostate Cancer Cells	58
Systematic evaluation of label-free protein quantification pipelines in 12 mouse syngeneic models	58
Large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients	58
Pharmacological activation of the mitochondrial stress protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma	58
Non-clinical identification and characterization of KRAS G12D inhibitors	57
T cell receptor beta constant 1 as a potential marker to better assess T cell clonality in skin samples	56
Impact of establishing a genetic clinic in conjunction with clinical practice in India	56
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas	56
In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations	56
Preoperative accelerated partial breast irradiation in locally recurrent breast cancer patients	55
The Punjab breast cancer AI-digital project: Implementing Artificial Intelligence-based triaging at scale for population-level screening of breast cancer	54
Contrast-enhanced mammography (CEM) with magnetic tracer as an alternative to MRI	54